549 Shares in McKesson Co. (NYSE:MCK) Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC purchased a new position in McKesson Co. (NYSE:MCK - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 549 shares of the company's stock, valued at approximately $313,000.

Several other institutional investors also recently bought and sold shares of the company. RPg Family Wealth Advisory LLC purchased a new stake in shares of McKesson during the third quarter valued at approximately $31,000. Synergy Asset Management LLC bought a new position in McKesson in the 4th quarter valued at approximately $32,000. Crews Bank & Trust purchased a new stake in McKesson during the 4th quarter valued at $33,000. Creative Capital Management Investments LLC bought a new stake in shares of McKesson in the 4th quarter worth $44,000. Finally, Bruce G. Allen Investments LLC raised its stake in shares of McKesson by 51.9% in the fourth quarter. Bruce G. Allen Investments LLC now owns 82 shares of the company's stock worth $47,000 after purchasing an additional 28 shares during the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Trading Up 0.4 %

NYSE MCK traded up $2.58 on Friday, reaching $668.25. 566,680 shares of the stock were exchanged, compared to its average volume of 837,100. McKesson Co. has a one year low of $464.42 and a one year high of $672.00. The firm has a market capitalization of $83.75 billion, a PE ratio of 30.60, a PEG ratio of 1.29 and a beta of 0.52. The company's 50-day simple moving average is $623.58 and its two-hundred day simple moving average is $579.34.

Remove Ads

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Sell-side analysts forecast that McKesson Co. will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd will be paid a $0.71 dividend. The ex-dividend date is Monday, March 3rd. This represents a $2.84 annualized dividend and a yield of 0.42%. McKesson's payout ratio is 13.00%.

Insider Activity

In other McKesson news, CEO Brian S. Tyler sold 8,961 shares of McKesson stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $600.66, for a total value of $5,382,514.26. Following the sale, the chief executive officer now owns 69,625 shares of the company's stock, valued at $41,820,952.50. The trade was a 11.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Leann B. Smith sold 188 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $609.59, for a total value of $114,602.92. Following the transaction, the executive vice president now owns 1,051 shares of the company's stock, valued at $640,679.09. This represents a 15.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,689 shares of company stock worth $11,187,351 over the last quarter. Insiders own 0.11% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on MCK shares. Bank of America reduced their price objective on McKesson from $680.00 to $650.00 and set a "buy" rating for the company in a report on Monday, January 6th. Mizuho started coverage on shares of McKesson in a report on Wednesday, December 4th. They set a "neutral" rating and a $630.00 price objective for the company. Evercore ISI raised their target price on shares of McKesson from $650.00 to $675.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Morgan Stanley boosted their target price on shares of McKesson from $612.00 to $642.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. Finally, StockNews.com downgraded McKesson from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $649.36.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.